Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 7/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.50 |
| ▸ | CCKBR | P32239 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171646 | 0.85 | ACE (0.62) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31171654 | 0.83 | ACE (0.59) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31171653 | 0.82 | CASP1 (0.58) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31220181 | 0.81 | CASP1 (0.60) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31171681 | 0.81 | CASP1 (0.57) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31171635 | 0.81 | CASP1 (0.55) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL14015903 | 0.81 | CASP1 (0.55) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL31171651 | 0.81 | ACE (0.59) | CASP1CASP3CASP7EDNRAACE | |
| SCHEMBL21955442 | 0.80 | DPP3 (0.47) | CASP1CASP3CASP7CCKBR | |
| SCHEMBL10316474 | 0.80 | CASP1 (0.56) | CASP1CASP3CASP7EDNRAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | CASP1 1529/4885CASP3 623/4885CASP7 833/4885 |
| US-11241473-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | CASP1 1529/4885CASP3 623/4885CASP7 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.